You are here:

Clopidogrel (Plavix®)

Advice

Following a full submission

Clopidogrel (Plavix) is accepted for restricted use within NHS Scotland for the treatment of acute coronary syndrome (without ST-segment elevation) in combination with aspirin. It should be initiated only during an inpatient stay and only in patients in whom a diagnosis of acute coronary syndrome is confirmed with ECG changes or raised cardiac enzymes/markers. The maximum benefit appears within 3 months of starting treatment and the available information suggests that there is loss of benefit on stopping treatment.

Benefits are greatest in patients with a high Thrombosis In Myocardial Infarction (TIMI) risk score (5 – 7).

Drug Details

Drug Name: Clopidogrel (Plavix®)
SMC Drug ID: 88/04
Manufacturer: Sanofi-Aventis
Indication: Prevention of atherothrombotic events in acute coronary syndrome
BNF Category:
Sub Category: 2.9 Antiplatelet drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 8 March 2004

Back